<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01858766</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-342-0102</org_study_id>
    <nct_id>NCT01858766</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naive Subjects With Chronic HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the antiviral efficacy, safety, and
      tolerability of sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV)
      in treatment-naive adults with chronic genotype (GT) 1, 2, 3, 4, 5, or 6 hepatitis C virus
      (HCV) infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</measure>
    <time_frame>Posttreatment Week 12</time_frame>
    <description>SVR12 was defined as HCV RNA &lt; the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</measure>
    <time_frame>Posttreatment Weeks 4 and 24</time_frame>
    <description>SVR4 and SVR 24 were defined as HCV RNA &lt; LLOQ at 4 and 24 weeks after stopping study treatment, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Failure</measure>
    <time_frame>Up to Posttreatment Week 24</time_frame>
    <description>Virologic failure was defined as:
On-treatment virologic failure:
Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ while on treatment), or
Rebound (confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or
Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)
Virologic relapse:
Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at last on-treatment visit.</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">379</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>SOF+VEL 25 mg 12 Weeks (GT1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 100 mg 12 Weeks (GT1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 25 mg 12 Weeks (GT2/4/5/6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 25 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 100 mg 12 Weeks (GT2/4/5/6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 2, 4, 5, or 6 HCV infection will receive SOF+VEL 100 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 25 mg 12 Weeks (GT3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 3 HCV infection will receive SOF+VEL 25 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 100 mg 12 Weeks (GT3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 3 HCV infection will receive SOF+VEL 100 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 25 mg 8 Weeks (GT1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 25 mg + RBV 8 Weeks (GT1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 100 mg 8 Weeks (GT1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 100 mg + RBV 8 Weeks (GT1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 25 mg 8 Weeks (GT2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 25 mg + RBV 8 Weeks (GT2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 2 HCV infection will receive SOF+VEL 25 mg plus RBV for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 100 mg 8 Weeks (GT2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+VEL 100 mg + RBV 8 Weeks (GT2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 2 HCV infection will receive SOF+VEL 100 mg plus RBV for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF</intervention_name>
    <description>400 mg tablet administered orally once daily</description>
    <arm_group_label>SOF+VEL 25 mg 12 Weeks (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg 12 Weeks (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg 12 Weeks (GT2/4/5/6)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg 12 Weeks (GT2/4/5/6)</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg 12 Weeks (GT3)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg 12 Weeks (GT3)</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg 8 Weeks (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg + RBV 8 Weeks (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg 8 Weeks (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg + RBV 8 Weeks (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg 8 Weeks (GT2)</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg + RBV 8 Weeks (GT2)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg 8 Weeks (GT2)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg + RBV 8 Weeks (GT2)</arm_group_label>
    <other_name>GS-7977</other_name>
    <other_name>PSI-7977</other_name>
    <other_name>Sovaldi®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VEL</intervention_name>
    <description>Tablet administered orally once daily</description>
    <arm_group_label>SOF+VEL 25 mg 12 Weeks (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg 12 Weeks (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg 12 Weeks (GT2/4/5/6)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg 12 Weeks (GT2/4/5/6)</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg 12 Weeks (GT3)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg 12 Weeks (GT3)</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg 8 Weeks (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg + RBV 8 Weeks (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg 8 Weeks (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg + RBV 8 Weeks (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg 8 Weeks (GT2)</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg + RBV 8 Weeks (GT2)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg 8 Weeks (GT2)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg + RBV 8 Weeks (GT2)</arm_group_label>
    <other_name>GS-5816</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <description>200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (&lt; 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)</description>
    <arm_group_label>SOF+VEL 25 mg + RBV 8 Weeks (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg + RBV 8 Weeks (GT1)</arm_group_label>
    <arm_group_label>SOF+VEL 25 mg + RBV 8 Weeks (GT2)</arm_group_label>
    <arm_group_label>SOF+VEL 100 mg + RBV 8 Weeks (GT2)</arm_group_label>
    <other_name>Ribasphere®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic HCV infection

          -  Body mass index (BMI) ≥ 18 kg/m^2

          -  HCV RNA ≥ 10000 IU/mL at screening

          -  Use of highly effective contraception methods if female of childbearing potential or
             sexually active male

          -  Must not have cirrhosis

        Exclusion Criteria:

          -  Current or prior history of clinically significant illness other than HCV

          -  Screening ECG with clinically significant abnormalities

          -  Prior exposure to HCV specific direct acting antiviral agent

          -  Prior treatment of HCV with interferon or ribavirin

          -  Pregnant or nursing female or male with pregnant female partner

          -  Chronic liver disease of non-HCV etiology

          -  Hepatitis B

          -  Active drug abuse

          -  Use of any prohibited concomitant medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John McNally, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruane Peter J MD Incorporated</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntington Medical Research Institutes Liver Center</name>
      <address>
        <city>Pasedena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Grp</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Associates Research Group, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permante</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Center for Clinical Trials Research</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borland-Groover Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Center of Gastroenterology, P.A</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Hepatitis C/Atlanta Medical Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30344</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists of Georgia, PC</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indianapolis Gastroenterology &amp; Hepatology, Inc.- ARC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Ctr</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ID Care</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest C.A.R.E. Center</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore/Long Island Jewish PRIME</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College-New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asheville Gastroenterology Associates, P.A.</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Research Associates, LLC</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Health Specialists, PA</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Health System</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Center For Liver Diseases</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Pittsburgh Healthcare System</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Gastroenterology</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Gastrointestinal Specialists Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Clinical Research Institute, LLC</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Transplant Physicians</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research, LTD d/b/a American Research Corporation</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Research</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INOVA Institute of Research &amp; Education</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Liver Institute of Virginia</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive and Liver Disease Specialists, Ltd.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion de Investigacion de Diego</name>
      <address>
        <city>Santurce</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Everson GT, Tran TT, Towner WJ , Davis MN, Wyles D, Nahass R, McNally J, Brainard DM, Han L, Doehle B, Mogalian E, Symonds WT, McHutchison JG, Morgan T, Chung RT. Safety and Efficacy of Treatment with the Interferon-Free, Ribavirin-Free Combination of Sofosbuvir + GS-5816 for 12 Weeks in Treatment Naive Patients with Genotype 1-6 HCV Infection. Journal of Hepatology, Volume 60, Issue 1, Supplement, Page S46. April 2014 (EASL 2014).</citation>
  </results_reference>
  <results_reference>
    <citation>Tran TT, Morgan TR, Thuluvath PJ, Etzkorn K, Hinestrosa F, Tong M, McNally J, Brainard DM, Han L, Doehle B, Mogalian E, McHutchison JG, Chung RT, Everson GT. Safety and Efficacy of Treatment with Sofosbuvir+ GS-5816±Ribavirin for 8 or 12 Weeks in Treatment Naïve Patients with Genotype 1-6 HCV Infection. Hepatology (2014), 60: 4 (suppl) 237A.</citation>
  </results_reference>
  <results_reference>
    <citation>Doehle B, Gontcharova V, Chodavarapu1 RK, McNally J, Chung RT, Everson GT, McHutchison JG, Miller MD, Mo H. Resistance Analysis of Treatment-Naive HCV Genotype 1-6 Infected Patients Treated with Sofosbuvir in Combination with GS-5816 for 12 Weeks. Hepatology (2014), 60: 4 (suppl) 1138A.</citation>
  </results_reference>
  <results_reference>
    <citation>Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, Etzkorn K, Hinestrosa F, Tong M, Rabinovitz M, McNally J, Brainard DM, Han L, Doehle B, McHutchison JG, Morgan T, Chung RT, Tran TT. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015 Dec 1;163(11):818-26. doi: 10.7326/M15-1000. Epub 2015 Nov 10.</citation>
    <PMID>26551051</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2013</study_first_submitted>
  <study_first_submitted_qc>May 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2013</study_first_posted>
  <results_first_submitted>July 27, 2016</results_first_submitted>
  <results_first_submitted_qc>July 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 15, 2016</results_first_posted>
  <disposition_first_submitted>January 16, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>January 16, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 28, 2015</disposition_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis</keyword>
  <keyword>HCV Genotype 1</keyword>
  <keyword>HCV Genotype 2</keyword>
  <keyword>HCV Genotype 3</keyword>
  <keyword>HCV Genotype 4</keyword>
  <keyword>HCV Genotype 5</keyword>
  <keyword>HCV Genotype 6</keyword>
  <keyword>treatment naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in the United States. The first participant was screened on 22 April 2013. The last study visit occurred on 12 August 2014.</recruitment_details>
      <pre_assignment_details>469 participants were screened.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SOF+VEL 25 mg 12 Weeks (GT1)</title>
          <description>Sofosbuvir (SOF) 400 mg tablet + velpatasvir (VEL) 25 mg tablet administered orally once daily for 12 weeks (genotype (GT) 1)</description>
        </group>
        <group group_id="P2">
          <title>SOF+VEL 100 mg 12 Weeks (GT1)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
        </group>
        <group group_id="P3">
          <title>SOF+VEL 25 mg 12 Weeks (GT2)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 2)</description>
        </group>
        <group group_id="P4">
          <title>SOF+VEL 100 mg 12 Weeks (GT2)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 2)</description>
        </group>
        <group group_id="P5">
          <title>SOF+VEL 25 mg 12 Weeks (GT3)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 3)</description>
        </group>
        <group group_id="P6">
          <title>SOF+VEL 100 mg 12 Weeks (GT3)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 3)</description>
        </group>
        <group group_id="P7">
          <title>SOF+VEL 25 mg 12 Weeks (GT4)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 4)</description>
        </group>
        <group group_id="P8">
          <title>SOF+VEL 100 mg 12 Weeks (GT4)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 4)</description>
        </group>
        <group group_id="P9">
          <title>SOF+VEL 25 mg 12 Weeks (GT5)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 5)</description>
        </group>
        <group group_id="P10">
          <title>SOF+VEL 25 mg 12 Weeks (GT6)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 6)</description>
        </group>
        <group group_id="P11">
          <title>SOF+VEL 100 mg 12 Weeks (GT6)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 6)</description>
        </group>
        <group group_id="P12">
          <title>SOF+VEL 25 mg 8 Weeks (GT1)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 8 weeks (genotype 1)</description>
        </group>
        <group group_id="P13">
          <title>SOF+VEL 25 mg + RBV 8 Weeks (GT1)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + ribavirin (RBV) tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 1)</description>
        </group>
        <group group_id="P14">
          <title>SOF+VEL 100 mg 8 Weeks (GT1)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 8 weeks (genotype 1)</description>
        </group>
        <group group_id="P15">
          <title>SOF+VEL 100 mg + RBV 8 Weeks (GT1)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 1)</description>
        </group>
        <group group_id="P16">
          <title>SOF+VEL 25 mg 8 Weeks (GT2)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 8 weeks (genotype 2)</description>
        </group>
        <group group_id="P17">
          <title>SOF+VEL 25 mg + RBV 8 Weeks (GT2)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 2)</description>
        </group>
        <group group_id="P18">
          <title>SOF+VEL 100 mg 8 Weeks (GT2)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 8 weeks (genotype 2)</description>
        </group>
        <group group_id="P19">
          <title>SOF+VEL 100 mg + RBV 8 Weeks (GT2)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="28"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="30"/>
                <participants group_id="P13" count="30"/>
                <participants group_id="P14" count="29"/>
                <participants group_id="P15" count="31"/>
                <participants group_id="P16" count="26"/>
                <participants group_id="P17" count="25"/>
                <participants group_id="P18" count="27"/>
                <participants group_id="P19" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="26"/>
                <participants group_id="P6" count="24"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="25"/>
                <participants group_id="P13" count="25"/>
                <participants group_id="P14" count="26"/>
                <participants group_id="P15" count="23"/>
                <participants group_id="P16" count="20"/>
                <participants group_id="P17" count="22"/>
                <participants group_id="P18" count="23"/>
                <participants group_id="P19" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="3"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="6"/>
                <participants group_id="P17" count="3"/>
                <participants group_id="P18" count="4"/>
                <participants group_id="P19" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized but Never Treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="1"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="3"/>
                <participants group_id="P15" count="5"/>
                <participants group_id="P16" count="5"/>
                <participants group_id="P17" count="2"/>
                <participants group_id="P18" count="3"/>
                <participants group_id="P19" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="3"/>
                <participants group_id="P16" count="1"/>
                <participants group_id="P17" count="1"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>SOF+VEL 25 mg 12 Weeks (GT1)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
        </group>
        <group group_id="B2">
          <title>SOF+VEL 100 mg 12 Weeks (GT1)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
        </group>
        <group group_id="B3">
          <title>SOF+VEL 25 mg 12 Weeks (GT2)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 2)</description>
        </group>
        <group group_id="B4">
          <title>SOF+VEL 100 mg 12 Weeks (GT2)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 2)</description>
        </group>
        <group group_id="B5">
          <title>SOF+VEL 25 mg 12 Weeks (GT3)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 3)</description>
        </group>
        <group group_id="B6">
          <title>SOF+VEL 100 mg 12 Weeks (GT3)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 3)</description>
        </group>
        <group group_id="B7">
          <title>SOF+VEL 25 mg 12 Weeks (GT4)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 4)</description>
        </group>
        <group group_id="B8">
          <title>SOF+VEL 100 mg 12 Weeks (GT4)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 4)</description>
        </group>
        <group group_id="B9">
          <title>SOF+VEL 25 mg 12 Weeks (GT5)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 5)</description>
        </group>
        <group group_id="B10">
          <title>SOF+VEL 25 mg 12 Weeks (GT6)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 6)</description>
        </group>
        <group group_id="B11">
          <title>SOF+VEL 100 mg 12 Weeks (GT6)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 6)</description>
        </group>
        <group group_id="B12">
          <title>SOF+VEL 25 mg 8 Weeks (GT1)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 8 weeks (genotype 1)</description>
        </group>
        <group group_id="B13">
          <title>SOF+VEL 25 mg + RBV 8 Weeks (GT1)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 1)</description>
        </group>
        <group group_id="B14">
          <title>SOF+VEL 100 mg 8 Weeks (GT1)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 8 weeks (genotype 1)</description>
        </group>
        <group group_id="B15">
          <title>SOF+VEL 100 mg + RBV 8 Weeks (GT1)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 1)</description>
        </group>
        <group group_id="B16">
          <title>SOF+VEL 25 mg 8 Weeks (GT2)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 8 weeks (genotype 2)</description>
        </group>
        <group group_id="B17">
          <title>SOF+VEL 25 mg + RBV 8 Weeks (GT2)</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 2)</description>
        </group>
        <group group_id="B18">
          <title>SOF+VEL 100 mg 8 Weeks (GT2)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 8 weeks (genotype 2)</description>
        </group>
        <group group_id="B19">
          <title>SOF+VEL 100 mg + RBV 8 Weeks (GT2)</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 2)</description>
        </group>
        <group group_id="B20">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="11"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="27"/>
            <count group_id="B6" value="27"/>
            <count group_id="B7" value="7"/>
            <count group_id="B8" value="7"/>
            <count group_id="B9" value="1"/>
            <count group_id="B10" value="4"/>
            <count group_id="B11" value="5"/>
            <count group_id="B12" value="30"/>
            <count group_id="B13" value="30"/>
            <count group_id="B14" value="29"/>
            <count group_id="B15" value="31"/>
            <count group_id="B16" value="26"/>
            <count group_id="B17" value="25"/>
            <count group_id="B18" value="26"/>
            <count group_id="B19" value="26"/>
            <count group_id="B20" value="377"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="11.4"/>
                    <measurement group_id="B2" value="49" spread="12.2"/>
                    <measurement group_id="B3" value="42" spread="14.6"/>
                    <measurement group_id="B4" value="53" spread="12.6"/>
                    <measurement group_id="B5" value="52" spread="10.8"/>
                    <measurement group_id="B6" value="50" spread="12.7"/>
                    <measurement group_id="B7" value="51" spread="16.1"/>
                    <measurement group_id="B8" value="56" spread="5.5"/>
                    <measurement group_id="B9" value="53">N/A because there is only 1 participant in this group.</measurement>
                    <measurement group_id="B10" value="57" spread="4.8"/>
                    <measurement group_id="B11" value="54" spread="9.3"/>
                    <measurement group_id="B12" value="50" spread="10.7"/>
                    <measurement group_id="B13" value="53" spread="8.5"/>
                    <measurement group_id="B14" value="55" spread="9.6"/>
                    <measurement group_id="B15" value="52" spread="13.8"/>
                    <measurement group_id="B16" value="52" spread="10.8"/>
                    <measurement group_id="B17" value="54" spread="11.5"/>
                    <measurement group_id="B18" value="54" spread="10.8"/>
                    <measurement group_id="B19" value="51" spread="9.4"/>
                    <measurement group_id="B20" value="52" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="14"/>
                    <measurement group_id="B13" value="12"/>
                    <measurement group_id="B14" value="13"/>
                    <measurement group_id="B15" value="15"/>
                    <measurement group_id="B16" value="11"/>
                    <measurement group_id="B17" value="8"/>
                    <measurement group_id="B18" value="14"/>
                    <measurement group_id="B19" value="16"/>
                    <measurement group_id="B20" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="16"/>
                    <measurement group_id="B13" value="18"/>
                    <measurement group_id="B14" value="16"/>
                    <measurement group_id="B15" value="16"/>
                    <measurement group_id="B16" value="15"/>
                    <measurement group_id="B17" value="17"/>
                    <measurement group_id="B18" value="12"/>
                    <measurement group_id="B19" value="10"/>
                    <measurement group_id="B20" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="7"/>
                    <measurement group_id="B19" value="5"/>
                    <measurement group_id="B20" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="26"/>
                    <measurement group_id="B13" value="29"/>
                    <measurement group_id="B14" value="27"/>
                    <measurement group_id="B15" value="30"/>
                    <measurement group_id="B16" value="23"/>
                    <measurement group_id="B17" value="23"/>
                    <measurement group_id="B18" value="19"/>
                    <measurement group_id="B19" value="21"/>
                    <measurement group_id="B20" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="1"/>
                    <measurement group_id="B20" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="3"/>
                    <measurement group_id="B14" value="5"/>
                    <measurement group_id="B15" value="5"/>
                    <measurement group_id="B16" value="2"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="2"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="26"/>
                    <measurement group_id="B13" value="27"/>
                    <measurement group_id="B14" value="24"/>
                    <measurement group_id="B15" value="24"/>
                    <measurement group_id="B16" value="22"/>
                    <measurement group_id="B17" value="23"/>
                    <measurement group_id="B18" value="24"/>
                    <measurement group_id="B19" value="25"/>
                    <measurement group_id="B20" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV Genotype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Genotype 1a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="25"/>
                    <measurement group_id="B13" value="25"/>
                    <measurement group_id="B14" value="24"/>
                    <measurement group_id="B15" value="25"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 1b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="5"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 1g</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="26"/>
                    <measurement group_id="B17" value="25"/>
                    <measurement group_id="B18" value="26"/>
                    <measurement group_id="B19" value="26"/>
                    <measurement group_id="B20" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="0"/>
                    <measurement group_id="B20" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IL28b Status</title>
          <description>The CC, CT, and TT alleles are different forms of the IL28b gene.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>CC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="9"/>
                    <measurement group_id="B13" value="10"/>
                    <measurement group_id="B14" value="13"/>
                    <measurement group_id="B15" value="9"/>
                    <measurement group_id="B16" value="9"/>
                    <measurement group_id="B17" value="13"/>
                    <measurement group_id="B18" value="9"/>
                    <measurement group_id="B19" value="7"/>
                    <measurement group_id="B20" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="14"/>
                    <measurement group_id="B13" value="16"/>
                    <measurement group_id="B14" value="13"/>
                    <measurement group_id="B15" value="18"/>
                    <measurement group_id="B16" value="14"/>
                    <measurement group_id="B17" value="9"/>
                    <measurement group_id="B18" value="14"/>
                    <measurement group_id="B19" value="14"/>
                    <measurement group_id="B20" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="4"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="4"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="3"/>
                    <measurement group_id="B18" value="3"/>
                    <measurement group_id="B19" value="3"/>
                    <measurement group_id="B20" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                    <measurement group_id="B19" value="2"/>
                    <measurement group_id="B20" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV RNA</title>
          <units>log10 IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.4" spread="0.60"/>
                    <measurement group_id="B2" value="6.4" spread="0.74"/>
                    <measurement group_id="B3" value="6.5" spread="0.74"/>
                    <measurement group_id="B4" value="6.7" spread="0.78"/>
                    <measurement group_id="B5" value="6.4" spread="1.09"/>
                    <measurement group_id="B6" value="6.2" spread="0.74"/>
                    <measurement group_id="B7" value="6.2" spread="0.58"/>
                    <measurement group_id="B8" value="5.8" spread="0.55"/>
                    <measurement group_id="B9" value="7.0">N/A because there is only 1 participant in this group.</measurement>
                    <measurement group_id="B10" value="6.1" spread="0.89"/>
                    <measurement group_id="B11" value="6.7" spread="0.88"/>
                    <measurement group_id="B12" value="6.5" spread="0.69"/>
                    <measurement group_id="B13" value="6.5" spread="0.63"/>
                    <measurement group_id="B14" value="6.3" spread="0.85"/>
                    <measurement group_id="B15" value="6.6" spread="0.55"/>
                    <measurement group_id="B16" value="6.4" spread="0.87"/>
                    <measurement group_id="B17" value="6.6" spread="0.80"/>
                    <measurement group_id="B18" value="6.5" spread="0.74"/>
                    <measurement group_id="B19" value="6.7" spread="0.57"/>
                    <measurement group_id="B20" value="6.5" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HCV RNA Category</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 800,000 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="5"/>
                    <measurement group_id="B14" value="8"/>
                    <measurement group_id="B15" value="3"/>
                    <measurement group_id="B16" value="6"/>
                    <measurement group_id="B17" value="4"/>
                    <measurement group_id="B18" value="5"/>
                    <measurement group_id="B19" value="2"/>
                    <measurement group_id="B20" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 800,000 IU/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="25"/>
                    <measurement group_id="B13" value="25"/>
                    <measurement group_id="B14" value="21"/>
                    <measurement group_id="B15" value="28"/>
                    <measurement group_id="B16" value="20"/>
                    <measurement group_id="B17" value="21"/>
                    <measurement group_id="B18" value="21"/>
                    <measurement group_id="B19" value="24"/>
                    <measurement group_id="B20" value="303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</title>
        <description>SVR12 was defined as HCV RNA &lt; the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.</description>
        <time_frame>Posttreatment Week 12</time_frame>
        <population>Full Analysis Set: participants randomized into the study and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>SOF+VEL 25 mg 12 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
          </group>
          <group group_id="O2">
            <title>SOF+VEL 100 mg 12 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
          </group>
          <group group_id="O3">
            <title>SOF+VEL 25 mg 12 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 2)</description>
          </group>
          <group group_id="O4">
            <title>SOF+VEL 100 mg 12 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 2)</description>
          </group>
          <group group_id="O5">
            <title>SOF+VEL 25 mg 12 Weeks (GT3)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 3)</description>
          </group>
          <group group_id="O6">
            <title>SOF+VEL 100 mg 12 Weeks (GT3)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 3)</description>
          </group>
          <group group_id="O7">
            <title>SOF+VEL 25 mg 12 Weeks (GT4)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 4)</description>
          </group>
          <group group_id="O8">
            <title>SOF+VEL 100 mg 12 Weeks (GT4)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 4)</description>
          </group>
          <group group_id="O9">
            <title>SOF+VEL 25 mg 12 Weeks (GT5)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 5)</description>
          </group>
          <group group_id="O10">
            <title>SOF+VEL 25 mg 12 Weeks (GT6)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 6)</description>
          </group>
          <group group_id="O11">
            <title>SOF+VEL 100 mg 12 Weeks (GT6)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 6)</description>
          </group>
          <group group_id="O12">
            <title>SOF+VEL 25 mg 8 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 8 weeks (genotype 1)</description>
          </group>
          <group group_id="O13">
            <title>SOF+VEL 25 mg + RBV 8 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 1)</description>
          </group>
          <group group_id="O14">
            <title>SOF+VEL 100 mg 8 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 8 weeks (genotype 1)</description>
          </group>
          <group group_id="O15">
            <title>SOF+VEL 100 mg + RBV 8 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 1)</description>
          </group>
          <group group_id="O16">
            <title>SOF+VEL 25 mg 8 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 8 weeks (genotype 2)</description>
          </group>
          <group group_id="O17">
            <title>SOF+VEL 25 mg + RBV 8 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 2)</description>
          </group>
          <group group_id="O18">
            <title>SOF+VEL 100 mg 8 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 8 weeks (genotype 2)</description>
          </group>
          <group group_id="O19">
            <title>SOF+VEL 100 mg + RBV 8 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</title>
          <description>SVR12 was defined as HCV RNA &lt; the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.</description>
          <population>Full Analysis Set: participants randomized into the study and received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="30"/>
                <count group_id="O13" value="30"/>
                <count group_id="O14" value="29"/>
                <count group_id="O15" value="31"/>
                <count group_id="O16" value="26"/>
                <count group_id="O17" value="25"/>
                <count group_id="O18" value="26"/>
                <count group_id="O19" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="81.0" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="87.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                    <measurement group_id="O4" value="100.0" lower_limit="69.2" upper_limit="100.0"/>
                    <measurement group_id="O5" value="92.6" lower_limit="75.7" upper_limit="99.1"/>
                    <measurement group_id="O6" value="92.6" lower_limit="75.7" upper_limit="99.1"/>
                    <measurement group_id="O7" value="100.0" lower_limit="59.0" upper_limit="100.0"/>
                    <measurement group_id="O8" value="85.7" lower_limit="42.1" upper_limit="99.6"/>
                    <measurement group_id="O9" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O10" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O11" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                    <measurement group_id="O12" value="86.7" lower_limit="69.3" upper_limit="96.2"/>
                    <measurement group_id="O13" value="83.3" lower_limit="65.3" upper_limit="94.4"/>
                    <measurement group_id="O14" value="89.7" lower_limit="72.6" upper_limit="97.8"/>
                    <measurement group_id="O15" value="80.6" lower_limit="62.5" upper_limit="92.5"/>
                    <measurement group_id="O16" value="76.9" lower_limit="56.4" upper_limit="91.0"/>
                    <measurement group_id="O17" value="88.0" lower_limit="68.8" upper_limit="97.5"/>
                    <measurement group_id="O18" value="88.5" lower_limit="69.8" upper_limit="97.6"/>
                    <measurement group_id="O19" value="88.5" lower_limit="69.8" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</title>
        <time_frame>Up to 12 weeks</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>SOF+VEL 25 mg 12 Weeks</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (all genotypes)</description>
          </group>
          <group group_id="O2">
            <title>SOF+VEL 100 mg 12 Weeks</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (all genotypes)</description>
          </group>
          <group group_id="O3">
            <title>SOF+VEL 25 mg 8 Weeks</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 8 weeks (all genotypes)</description>
          </group>
          <group group_id="O4">
            <title>SOF+VEL 25 mg + RBV 8 Weeks</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (all genotypes)</description>
          </group>
          <group group_id="O5">
            <title>SOF+VEL 100 mg 8 Weeks</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 8 weeks (all genotypes)</description>
          </group>
          <group group_id="O6">
            <title>SOF+VEL 100 mg + RBV 8 Weeks</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (all genotypes)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</title>
          <population>Safety Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="55"/>
                <count group_id="O6" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.8"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</title>
        <description>SVR4 and SVR 24 were defined as HCV RNA &lt; LLOQ at 4 and 24 weeks after stopping study treatment, respectively.</description>
        <time_frame>Posttreatment Weeks 4 and 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>SOF+VEL 25 mg 12 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
          </group>
          <group group_id="O2">
            <title>SOF+VEL 100 mg 12 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
          </group>
          <group group_id="O3">
            <title>SOF+VEL 25 mg 12 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 2)</description>
          </group>
          <group group_id="O4">
            <title>SOF+VEL 100 mg 12 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 2)</description>
          </group>
          <group group_id="O5">
            <title>SOF+VEL 25 mg 12 Weeks (GT3)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 3)</description>
          </group>
          <group group_id="O6">
            <title>SOF+VEL 100 mg 12 Weeks (GT3)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 3)</description>
          </group>
          <group group_id="O7">
            <title>SOF+VEL 25 mg 12 Weeks (GT4)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 4)</description>
          </group>
          <group group_id="O8">
            <title>SOF+VEL 100 mg 12 Weeks (GT4)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 4)</description>
          </group>
          <group group_id="O9">
            <title>SOF+VEL 25 mg 12 Weeks (GT5)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 5)</description>
          </group>
          <group group_id="O10">
            <title>SOF+VEL 25 mg 12 Weeks (GT6)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 6)</description>
          </group>
          <group group_id="O11">
            <title>SOF+VEL 100 mg 12 Weeks (GT6)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 6)</description>
          </group>
          <group group_id="O12">
            <title>SOF+VEL 25 mg 8 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 8 weeks (genotype 1)</description>
          </group>
          <group group_id="O13">
            <title>SOF+VEL 25 mg + RBV 8 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 1)</description>
          </group>
          <group group_id="O14">
            <title>SOF+VEL 100 mg 8 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 8 weeks (genotype 1)</description>
          </group>
          <group group_id="O15">
            <title>SOF+VEL 100 mg + RBV 8 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 1)</description>
          </group>
          <group group_id="O16">
            <title>SOF+VEL 25 mg 8 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 8 weeks (genotype 2)</description>
          </group>
          <group group_id="O17">
            <title>SOF+VEL 25 mg + RBV 8 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 2)</description>
          </group>
          <group group_id="O18">
            <title>SOF+VEL 100 mg 8 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 8 weeks (genotype 2)</description>
          </group>
          <group group_id="O19">
            <title>SOF+VEL 100 mg + RBV 8 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</title>
          <description>SVR4 and SVR 24 were defined as HCV RNA &lt; LLOQ at 4 and 24 weeks after stopping study treatment, respectively.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="30"/>
                <count group_id="O13" value="30"/>
                <count group_id="O14" value="29"/>
                <count group_id="O15" value="31"/>
                <count group_id="O16" value="26"/>
                <count group_id="O17" value="25"/>
                <count group_id="O18" value="26"/>
                <count group_id="O19" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="81.0" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="87.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                    <measurement group_id="O4" value="100.0" lower_limit="69.2" upper_limit="100.0"/>
                    <measurement group_id="O5" value="92.6" lower_limit="75.7" upper_limit="99.1"/>
                    <measurement group_id="O6" value="100.0" lower_limit="87.2" upper_limit="100.0"/>
                    <measurement group_id="O7" value="100.0" lower_limit="59.0" upper_limit="100.0"/>
                    <measurement group_id="O8" value="85.7" lower_limit="42.1" upper_limit="99.6"/>
                    <measurement group_id="O9" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O10" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O11" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                    <measurement group_id="O12" value="86.7" lower_limit="69.3" upper_limit="96.2"/>
                    <measurement group_id="O13" value="83.3" lower_limit="65.3" upper_limit="94.4"/>
                    <measurement group_id="O14" value="93.1" lower_limit="77.2" upper_limit="99.2"/>
                    <measurement group_id="O15" value="87.1" lower_limit="70.2" upper_limit="96.4"/>
                    <measurement group_id="O16" value="88.5" lower_limit="69.8" upper_limit="97.6"/>
                    <measurement group_id="O17" value="88.0" lower_limit="68.8" upper_limit="97.5"/>
                    <measurement group_id="O18" value="92.3" lower_limit="74.9" upper_limit="99.1"/>
                    <measurement group_id="O19" value="88.5" lower_limit="69.8" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6" lower_limit="75.7" upper_limit="99.1"/>
                    <measurement group_id="O2" value="100.0" lower_limit="87.7" upper_limit="100.0"/>
                    <measurement group_id="O3" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                    <measurement group_id="O4" value="100.0" lower_limit="69.2" upper_limit="100.0"/>
                    <measurement group_id="O5" value="92.6" lower_limit="75.7" upper_limit="99.1"/>
                    <measurement group_id="O6" value="92.6" lower_limit="75.7" upper_limit="99.1"/>
                    <measurement group_id="O7" value="100.0" lower_limit="59.0" upper_limit="100.0"/>
                    <measurement group_id="O8" value="85.7" lower_limit="42.1" upper_limit="99.6"/>
                    <measurement group_id="O9" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O10" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O11" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                    <measurement group_id="O12" value="86.7" lower_limit="69.3" upper_limit="96.2"/>
                    <measurement group_id="O13" value="83.3" lower_limit="65.3" upper_limit="94.4"/>
                    <measurement group_id="O14" value="89.7" lower_limit="72.6" upper_limit="97.8"/>
                    <measurement group_id="O15" value="80.6" lower_limit="62.5" upper_limit="92.5"/>
                    <measurement group_id="O16" value="76.9" lower_limit="56.4" upper_limit="91.0"/>
                    <measurement group_id="O17" value="88.0" lower_limit="68.8" upper_limit="97.5"/>
                    <measurement group_id="O18" value="88.5" lower_limit="69.8" upper_limit="97.6"/>
                    <measurement group_id="O19" value="88.5" lower_limit="69.8" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Failure</title>
        <description>Virologic failure was defined as:
On-treatment virologic failure:
Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ while on treatment), or
Rebound (confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or
Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)
Virologic relapse:
Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at last on-treatment visit.</description>
        <time_frame>Up to Posttreatment Week 24</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>SOF+VEL 25 mg 12 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
          </group>
          <group group_id="O2">
            <title>SOF+VEL 100 mg 12 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 1)</description>
          </group>
          <group group_id="O3">
            <title>SOF+VEL 25 mg 12 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 2)</description>
          </group>
          <group group_id="O4">
            <title>SOF+VEL 100 mg 12 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 2)</description>
          </group>
          <group group_id="O5">
            <title>SOF+VEL 25 mg 12 Weeks (GT3)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 3)</description>
          </group>
          <group group_id="O6">
            <title>SOF+VEL 100 mg 12 Weeks (GT3)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 3)</description>
          </group>
          <group group_id="O7">
            <title>SOF+VEL 25 mg 12 Weeks (GT4)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 4)</description>
          </group>
          <group group_id="O8">
            <title>SOF+VEL 100 mg 12 Weeks (GT4)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 4)</description>
          </group>
          <group group_id="O9">
            <title>SOF+VEL 25 mg 12 Weeks (GT5)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 5)</description>
          </group>
          <group group_id="O10">
            <title>SOF+VEL 25 mg 12 Weeks (GT6)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (genotype 6)</description>
          </group>
          <group group_id="O11">
            <title>SOF+VEL 100 mg 12 Weeks (GT6)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (genotype 6)</description>
          </group>
          <group group_id="O12">
            <title>SOF+VEL 25 mg 8 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 8 weeks (genotype 1)</description>
          </group>
          <group group_id="O13">
            <title>SOF+VEL 25 mg + RBV 8 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 1)</description>
          </group>
          <group group_id="O14">
            <title>SOF+VEL 100 mg 8 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 8 weeks (genotype 1)</description>
          </group>
          <group group_id="O15">
            <title>SOF+VEL 100 mg + RBV 8 Weeks (GT1)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 1)</description>
          </group>
          <group group_id="O16">
            <title>SOF+VEL 25 mg 8 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 8 weeks (genotype 2)</description>
          </group>
          <group group_id="O17">
            <title>SOF+VEL 25 mg + RBV 8 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 2)</description>
          </group>
          <group group_id="O18">
            <title>SOF+VEL 100 mg 8 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 8 weeks (genotype 2)</description>
          </group>
          <group group_id="O19">
            <title>SOF+VEL 100 mg + RBV 8 Weeks (GT2)</title>
            <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (genotype 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Failure</title>
          <description>Virologic failure was defined as:
On-treatment virologic failure:
Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA &lt; LLOQ while on treatment), or
Rebound (confirmed &gt; 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or
Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)
Virologic relapse:
Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA &lt; LLOQ at last on-treatment visit.</description>
          <population>Full Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="27"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="4"/>
                <count group_id="O11" value="5"/>
                <count group_id="O12" value="30"/>
                <count group_id="O13" value="30"/>
                <count group_id="O14" value="29"/>
                <count group_id="O15" value="31"/>
                <count group_id="O16" value="26"/>
                <count group_id="O17" value="25"/>
                <count group_id="O18" value="26"/>
                <count group_id="O19" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="7.4"/>
                    <measurement group_id="O6" value="7.4"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="10.0"/>
                    <measurement group_id="O13" value="16.7"/>
                    <measurement group_id="O14" value="10.3"/>
                    <measurement group_id="O15" value="16.1"/>
                    <measurement group_id="O16" value="23.1"/>
                    <measurement group_id="O17" value="8.0"/>
                    <measurement group_id="O18" value="11.5"/>
                    <measurement group_id="O19" value="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 weeks plus 30 days</time_frame>
      <desc>Safety Analysis Set</desc>
      <group_list>
        <group group_id="E1">
          <title>SOF+VEL 25 mg 12 Weeks</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 12 weeks (all genotypes)</description>
        </group>
        <group group_id="E2">
          <title>SOF+VEL 100 mg 12 Weeks</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 12 weeks (all genotypes)</description>
        </group>
        <group group_id="E3">
          <title>SOF+VEL 25 mg 8 Weeks</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily for 8 weeks (all genotypes)</description>
        </group>
        <group group_id="E4">
          <title>SOF+VEL 25 mg + RBV 8 Weeks</title>
          <description>SOF 400 mg tablet + VEL 25 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (all genotypes)</description>
        </group>
        <group group_id="E5">
          <title>SOF+VEL 100 mg 8 Weeks</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily for 8 weeks (all genotypes)</description>
        </group>
        <group group_id="E6">
          <title>SOF+VEL 100 mg + RBV 8 Weeks</title>
          <description>SOF 400 mg tablet + VEL 100 mg tablet administered orally once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 8 weeks (all genotypes)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Traumatic liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram ST segment elevation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosures</name_or_title>
      <organization>Gilead Sciences</organization>
      <email>ClinicalTrialDisclosures@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

